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Abstract
Objective: To evaluate the effectiveness of a non-pharmacological 
intervention for weight gain management in severe mental disorders. 
Method: An open, multicentre interventional study was conducted in 93 
mental health services. Patients concerned with weight gain were included 
in this study and received a 12-week 1-hour group intervention focused on 
nutrition counseling, lifestyle, physical activity and self-esteem. Weight, 
waist circumference and blood pressure were measured before and after 
the intervention. Results: 1,071 patients were enrolled in the study, and 
73.9% completed the 12-week intervention. Significant weight loss (Mean 
difference: 0.41, CI 95%: 0.18 to 0.64, p = 0.001) and a significant BMI 
reduction (Mean difference: 0.13, CI 95%: 0.04 to 0.22, p = 0.006) were 
observed. During the intervention 37 (4.4%) patients lost > 7% of their 
initial weight, 780 (92.5%) maintained their weight, and 26 (3.1%) of 
the patients had a meaningful weight gain (> 7%). There was a significant 
increase in the proportion of patients undertaking physical activity after 
the intervention (70.8%, p < 0.001). Conclusion: In this 3-month 
open study we found a small weight and waist reduction, and increased 
physical activity practice, suggesting a trend towards anthropometric 
profile improvement. However, further randomized-controlled trials are 
necessary to evaluate the efficacy and clinical relevance of this psychosocial 
intervention for weight gain. 
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Resumo
Objetivo: Avaliar a efetividade de uma intervenção não farmacológica no 
manejo do ganho de peso para pacientes com transtornos mentais graves. 
Método: Foi realizado um estudo aberto multicêntrico longitudinal em 
93 serviços de saúde. Pacientes preocupados com o peso foram incluídos e 
participaram de uma intervenção em grupo de uma hora de duração durante 
12 semanas com foco em educação alimentar, atividade física e autoestima. 
Peso, circunferência da cintura e pressão arterial foram avaliados antes e após 
a intervenção. Resultados: 1071 pacientes foram incluídos no estudo, 73,9% 
completaram a intervenção. Foram observados diminuição de peso e índice 
de massa corporal significativos (peso: diferença da média: 0,41, IC 95%: 
0,18-0,64, p = 0,001; índice de massa corporal: diferença da média: 0,13, 
IC 95%: 0,04-0,22, p = 0,006). Após a intervenção, 37 (4,4%) pacientes 
perderam mais que 7% do peso inicial, 780 (92,5%) mantiveram o peso e 
26 (3,1%) dos pacientes apresentaram ganho de peso acima de 7%.  Houve 
aumento da proporção de pacientes que praticavam atividade física (70,8%, 
 p < 0,001). Conclusão: Encontramos uma pequena redução de peso e 
cinturae aumento de atividade física, sugerindo uma tendência à melhora 
no perfil antropométrico. Ensaios clínicos controlados e randomizados são 
necessários para avaliar a eficácia e a relevância clínica dessa intervenção.
Descritores: Ganho de peso; Transtornos mentais; Atividade física; 
Esquizofrenia; Agentes antipsicóticos 
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Introduction
The increasing epidemic of obesity in the general population 
is associated with a variety of metabolic disturbances and serious 
health consequences such as cardiovascular disorders and diabetes 
mellitus.1 Patients with severe mental illness have a high prevalence 
of obesity in comparison with the general population.2,3 Several 
factors can be related to weight gain, such as poor dietary 
conditions, sedentary lifestyle and psychiatric medications such 
as antipsychotics, mood stabilizers and antidepressants.1,4
Although weight gain is an important clinical issue in the 
treatment of severe mental disorders, intervention studies in this 
context are scarce.5-7 At present, there is limited evidence for the 
effectiveness and safety of current pharmacological interventions 
OA-107
- resumo, colocar resultados em negrito
- pag 1, 1 col, 1 par, 4 linha, sobrescrever 1
- 5 linha, sobrescrever 2,3
- pag 2, 1 col, 4 par, 5 linha, colocar (1301/05) de-
pois de Comittee
- pag 4, 1 col, 3 par, penúltima linha, sobrescrever 16
- 2 col, 2 par, 5 linha, sobrescrever 23
- ref 16, tirar . depois de Scholarsh..
117 • Revista Brasileira de Psiquiatria • vol 33 • nº 2 • jun2011 
Intervention for weight gain
Revista Brasileira de Psiquiatria • vol 33 • nº 2 • jun2011 • 118
for weight control in patients taking antipsychotic medications.8-10 
Behavioral interventions involving physical activity and nutritional 
advice have, however, proved beneficial for this population.4 
In this study, we present and analyze results obtained from 
a national multicentric survey conducted to evaluate the 
effectiveness of weight gain management intervention in patients 
with severe mental disorders. 
Material and method
1. Study design
We performed an open, multicentric and longitudinal study 
in 93 mental health services for inpatients and outpatients from 
community and private mental health services.
The detailed explanation of the Wellness Program to the patients 
was conducted in every institution by a mental health professional. 
After this explanation, the patients were invited to participate 
in the study. This study was approved by the UNIFESP Ethics 
Committee (1301/05) and all participants signed an informed 
consent form after having received a thorough explanation of the 
entire procedure.
2. Intervention
The Wellness Program is a 12-week weight management 
intervention for patients with severe mental disorders.11 In the 
1-hour weekly group sessions topics including dietary choices, 
lifestyle, physical activity and self-esteem were discussed with 
outpatients and their relatives (Table 1). The groups were led 
by mental health professionals – nurses, occupational therapists, 
psychologists and dieticians – who were trained and supervised 
by our team based at the Schizophrenia Program, Universidade 
Federal de São Paulo, Brazil, with support from Eli Lilly Brazil. The 
structure of the whole intervention was properly documented, and 
all professionals received a manual and a set of DVDs explaining 
the program. Patients were kept on their usual psychiatric 
treatment without any interference on the part of the participating 
researchers. Patients that attended fewer than six sessions were 
considered to have dropped out.
3. Inclusion and exclusion criteria
Inclusion criteria were: (1) patients should be between 18 
and 65 years old and have a diagnosis of severe mental disorder. 
Severe mental illness was defined by diagnosis, disability and 
duration, and included psychotic disorders such as schizophrenia, 
schizoaffective disorder, manic-depressive disorder, autism and 
other serious disorders such as major depression, panic disorder 
and obsessive-compulsive disorder.12 (2) Patients should show an 
interest in at least one of the group topics; (3) patients should 
be taking antipsychotic medication and/or a mood stabilizer. 
Exclusion criteria were: (1) not having any concern about weight or 
dietary habits; (2) being an acutely psychotic or clinically unstable 
patient. Patients with other clinical conditions – e.g. diabetes 
mellitus and hypertension – and taking other medications were 
not excluded from this study.
4. Assessment
Sociodemographic data, diagnosis, medication in use and 
family history of obesity, hypertension, diabetes mellitus and/or 
dyslipidemia were registered. Body mass index (BMI) and waist 
circumference were considered the indicators for obesity and 
body fat distribution. Weight, height, waist circumference and 
blood pressure were measured before and after the intervention. 
Weight was evaluated without shoes, with the individuals wearing 
light clothes; waist circumference was measured at the level of 
the navel. Weight gain was considered abnormal if there was an 
increase superior to 7% of the initial weight.13 BMI is defined 
as the individual’s body weight (in kg) divided by the square of 
his height (in m) [BMI= weight (kg)/height2 (m2)²]. Measures 
were taken by the same investigator in all assessments. Physical 
activity levels were assessed by questions evaluating whether 
they were currently doing any kind of physical activity and the 
frequency of any physical activity. In the Wellness Program, all 
types of physical activity were considered such as housecleaning, 
dog walking, gardening, walking, swimming and physical exercise 
in general. Each patient had a record of their physical activity 
at baseline and after the intervention. During the program, the 
way in which physical activity was incorporated into their daily 
routine was recorded. Simple questions like “what you did before 
and what you do now” related to physical activity were noted in 
the records. All participants were encouraged to increase physical 
activity in their lives through simple actions like getting off the 
bus a few stops early, cleaning the yard, walking with friends. 
This was a qualitative measure that has intrinsic limitations since 
it was not feasible to monitor the amount of physical activity of 
each individual.
5. Statistical analysis 
Data analysis was performed using the software SPSS 11.5. 
Normality was tested using Kolmogorov-Smirnov test. The 
Student’s paired t-test was used to evaluate the statistical 
significance of weight, BMI, waist and blood pressure changes 
after the intervention. We performed a general linear model 
for weight and BMI using, as a cluster factor, the mental health 
institution and the point of assessment as a repeated measure to 
check if the treatment institution influences the main outcome. 
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The McNemar test was used to analyze physical activity changes. 
We considered p < 0.05, two-tailed in all tests. 
A categorical variable associated with weight change after 
intervention was created and included three classes of patients: 
patients with more than 7% of weight loss, patients whose weight 
was not significantly altered (i.e. who had less than 7% of weight 
gain or loss) and patients who had more than 7% of weight 
gain. This cutoff was established according to previous studies 
evaluating weight gain in schizophrenia.6,13 Waist was presented 
stratified by gender because of the clinical importance of this 
measure to diagnose metabolic syndrome.
Results 
Ninety-three psychiatric services were given training, with an 
average of 11 patients per group. One thousand and seventy-
one patients were assigned to the intervention and their 
sociodemographic data and clinical characteristics are found in 
Table 2. The vast majority of the patients (648, 63.8%) had a 
diagnosis of schizophrenia or other psychotic disorder, and 278 
(27.4%) had a diagnosis of mood disorders. At baseline, 806 
(80.9%) patients were taking antipsychotic drugs: 272 (27.3%) 
were taking first-generation antipsychotics, 320 (32.1%) were 
taking second-generation antipsychotic drugs, and 214 (21.5%) 
were taking both second and first generation antipsychotics.
The majority of the patients (794, 73.9%) attended 6 or more 
sessions, with an average of 10.5 (SD: 2.1). However, 26.1% 
dropped out with an average of 3.4 (SD: 1.2) attended sessions. 
Reasons for dropout included recurrence, declining to participate, 
personal issues, lost contact and others. No differences were found 
between patients who completed the intervention and dropouts 
regarding gender, age, BMI at baseline, use of antipsychotics and 
mood stabilizers (p > 0.05). 
After the intervention, patients showed a significant weight 
loss of 0.41, CI 95%: 0.18 to 0.64, p = 0.001 and significant 
BMI reduction (Mean difference: 0.13, CI 95%: 0.04 to 0.22, 
p = 0.006) - Table 3. The treatment institution did not have a major 
influence on the main outcome reaching similar results for weight 
(p = 0.003) and for BMI (p = 0.022). Mean weight difference after 
controlling for the institutions was 0.39 (CI95%:0.13 to 0.65) 
and BMI mean difference was 0.12 (CI 95%: 0.017 to 0.228). 
During the intervention, 37 (4.4%) patients lost more than 7% 
of their initial weight, 780 (92.5%) maintained their weight 
(lost less than 7% or gained up to 7% of the initial weight) and 
only 26 (3.1%) of the patients had a meaningful weight gain (> 
7%). Patients taking 1st or 2nd generation antipsychotic drugs 
showed no significant differences in weight loss (p = 0.904) or 
BMI reduction (p = 0.658). Comparisons between patients with 
schizophrenia versus patients with mood disorders showed no 
significant differences in weight, BMI, waist or blood pressure 
(p > 0.05). After the intervention, both male and female patients 
presented a significant waist reduction (Table 3); p < 0.001.
There was a marked increase in physical activity after the 
intervention; at baseline 446 (51.5%) patients were practising 
some kind of physical activity while after the intervention this 
number increased to 613 (70.8%, p < 0.001).
Discussion 
This is the largest real-world pragmatic multicentric national 
study of a non-pharmacological intervention for weight 
management involving 1071 patients with schizophrenia and other 
severe mental disorders from 93 health services distributed all over 
the country. We found a significant weight and waist circumference 
reduction. However, the magnitude of the reduction in weight 
(0.41kg) and waist (1cm in female and 0.8cm in male) was small 
and the clinical impact of this change is questionable. 
Although some studies have focused on individual interventions 
for weight gain management,6,14,15 the purpose of our study was 
to evaluate a group intervention. This has implications if the 
intervention were to be implemented by the public health services, 
as the group aspect of the intervention would prove to be cost 
effective. The content of the intervention was similar to other 
published studies focusing on psychoeducation about healthy 
nutrition, physical activity and self-esteem.16,17 Although longer 
interventions are better for weight loss programs, several mental 
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drug (214, 21.5%). On the other hand, the data shows that 
weight gain is not restricted to treatment using 2nd generation 
antipsychotic drugs, given that 27.3% of the patients were taking 
1st generation antipsychotic drugs and 19.2% were not taking 
antipsychotic drugs at all. 
Weight management strategies are of great importance and are 
widely used in the general population. Interventions focused on 
populations with severe mental health disorders are greatly needed 
in order to implement healthy habits, prevent cardiovascular 
disorders and improve quality of life.23 This study has shown that 
the Wellness Program intervention is uncomplicated, feasible in 
a wide variety of mental health teams in Brazil, and it was found 
that the great majority of the patients maintained their weight. We 
are conducting a randomized controlled trial in this population 
to evaluate the effectiveness of the intervention in weight gain 
prevention.
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health studies have been reporting 12-week interventions similar 
to ours.14,15,17,18 
Compliance with obesity treatment is hard to achieve even in 
the general population, considering that most obese people, if left 
untreated for 3 to 5 years, would probably gain 0.5-1kg per year.19 
The problem is even worse in patients with chronic and severe 
mental disorders due to unhealthy lifestyle, use of antipsychotics 
and negative symptoms. Even considering these conditions, 
our study had a good compliance rate, with 73.9% of patients 
completing the intervention, a value similar to those reported in 
other studies (which ranged from 49% to 100%).14-16 
We found an average decrease of 0.41kg with a related reduction 
of 0.13kg/m² in the BMI, 92.5% of the subjects having maintained 
their weight. These results are compatible with those reported by 
Littrel et al., who reported a 0.02kg weight loss in patients who 
had attended group sessions.16 After the intervention, patients 
showed a signifi cant waist reduction, similar to other studies.13,20 
It is also important to remark that we observed an increase in 
physical activity after the intervention. This is relevant, as there is 
increasing evidence that modest physical activity can reduce the 
risk of cardiovascular diseases, independent of the weight status.21,22 
While the results are encouraging, the study has some limitations, 
such as the relatively short period of follow-up (12 weeks) and 
the absence of a control group. However, patients have changed 
metabolic parameters and exercise habits in the short term. The 
results suggest that there is an improvement or maintenance 
of weight and BMI. The effectiveness of our intervention in 
preventing weight gain is, however, limited by the absence of a 
control group. The fact that the average age of participants was 
40.3 and mean BMI was 31.3kg/m2 indicates that the majority 
of patients had already experienced weight gain, further limiting 
speculation about the effectiveness of the intervention in weight 
gain prevention because the weight changes are smaller in obese 
patients. The intervention was customized for this population and 
a randomized-controlled trial is necessary to evaluate the effects 
of the intervention in weight gain prevention. 
The naturalistic design and the presence of a large and 
representative sample allow us to estimate which factors are, 
“in the real world”, associated with weight gain complaints on 
the part of mental health patients. We have echoed the recent 
concerns highlighted in the literature, since the majority of the 
patients were taking 2nd generation compounds in monotherapy 
(320, 32.1%) or combined with a 1st generation antipsychotic 
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